High‐density lipoproteins, platelets and the pathogenesis of atherosclerosis
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: 1. Prospective and interventional studies demonstrate an inverse relationship between plasma high‐density lipoprotein (HDL)–cholesterol and the incidence of coronary artery disease. Although the atheroprotective effects of HDL are usually attributed to the reverse cholesterol transport, in which HDL shuttles cholesterol from cells in the arterial wall to the liver, other mechanisms are also under investigation. 2. Platelets are involved in both the initiation and progression of atherosclerotic lesions. In addition, the formation of thrombi over ruptured atherosclerotic plaques results in the narrowing or complete occlusion of coronary arteries. Current experimental evidence suggests that HDL may exert antiplatelet effects and thereby counteract the development of atherothrombotic vascular disease. 3. In vitro studies show that HDL inhibits agonist‐stimulated platelet aggregation, fibrinogen binding, granule secretion and liberation of thromboxane A 2. Inhibitory effects of HDL are mediated, in part, by scavenger receptor type B1 and/or the apolipoprotein E receptor apoER2/LRP8 and are linked to the induction of intracellular signalling cascades encompassing stimulation of protein kinase C, cytoplasmatic alkalization and generation of nitric oxide. 4. Populational studies demonstrate that there is an inverse association between plasma HDL levels and recurrent venous thromboembolism. In addition, HDL–cholesterol has been identified as an independent predictor of acute platelet thrombus formation. The administration of reconstituted HDL particles in humans attenuates ex vivo platelet activation. 5. The present review summarizes recent advances in understanding HDL–platelet interactions and discusses the potential use of HDL‐like particles in the therapy of thrombosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“effects of medication with an HDL-elevating compound (torcetrapib) on cardiovascular mortality have been reported.(115) Although treatment with torcetrapib led to a considerable increase in plasma HDL-C in that study, the functional properties of HDL in treated subjects with respect to modulating platelet reactivity r…”
BackgroundPlatelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Podrez, E. A., Byzova, T. V., Febbraio, M., Salomon, R. G., Ma, Y., Valiyaveettil, M., Poliakov, E., Sun, M., Finton, P. J., Curtis, B. R., et al. (2007) · Nature Medicine · doi:10.1038/nm1626 · Cited by 513
Bergt, C., Pennathur, S., Fu, X., Byun, J., O'Brien, K., McDonald, T. O., Singh, P., Anantharamaiah, G. M., Chait, A., Brunzell, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405292101 · Cited by 454 · cited 11×
“The concept of reverse cholesterol transport is supported by a number of experimental studies and has recently been subject to several excellent reviews.3,4 However, some observations suggest that participation in reverse cholesterol transport does not tap the full anti-atherogenic potential of HDL.”
BackgroundInfluentialApolipoprotein E Inhibits Platelet Aggregation through the L-Arginine:Nitric Oxide Pathway
Riddell, D. R., Graham, A., & Owen, J. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.89 · Cited by 209 · cited 2×
“It has been shown that incubation of platelets with HDL leads to the release of diacylglycerol (DAG) from the plasma membrane phosphatidylcholine and to subsequent activation of protein kinase C (PKC), which, in turn, stimulates the Na+ ⁄H+ antiport, promotes alkalization of the cytoplasmic compartment and inhibits ‘‘…”
Identification and characterization of LRP8 (apoER2) in human blood platelets
Riddell, D. R., Vinogradov, D. V., Stannard, A. K., Chadwick, N., & Owen, J. S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34910-5 · Cited by 106
Cited by
Fibrinogen as a key regulator of inflammation in disease
Davalos, D., & Akassoglou, K. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-011-0290-8 · Cited by 922
Biological activities of HDL subpopulations and their relevance to cardiovascular disease
Camont, L., Chapman, M. J., & Kontush, A. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.013 · Cited by 471
Shah, A. S., Tan, L., Long, J. L., & Davidson, W. S. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r035725 · Cited by 351
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
Metadata
- Authors
- Nofer, J., Brodde, M. F., & Kehrel, B. E.
- Venue
- Clinical and Experimental Pharmacology and Physiology
- Publisher
- Wiley
- Published
- 2010-06-17
- Volume
- 37
- Issue
- 7
- Pages
- 726-735
- ISSN
- 0305-1870 (ISSN-L)
- 1440-1681
- OpenAlex
- W1955965722
- Cited by
- 122
- References
- 5
- FWCI
- 15.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High‐density lipoproteins, platelets and the pathogenesis of atherosclerosis. https://app.cochat.ai/papers/10.1111/j.1440-1681.2010.05377.x
- The paper
- Nofer, J., Brodde, M. F., & Kehrel, B. E. (2010). High‐density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/j.1440-1681.2010.05377.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.